Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orgenesis Inc.

www.orgenesis.com

Latest From Orgenesis Inc.

Deals Shaping The Medical Industry, January 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2015.

BioPharmaceutical Medical Device

Start-Up Quarterly Statistics, Q1 2015

In Q1 2015 start-ups raised $2.74 billion, a new record. Biopharma companies penned 37 alliances; 13 start-ups were acquired across all industries.

BioPharmaceutical Medical Device

Growing Globally And Tapping Expertise: Tales From Bio Korea

South Korea’s Boryung Pharm has now signed $1 billion worth of global agreements for its antihypertensive Kanarb, while U.S. regenerative medicine company Orgenesis, which is working to cure type 1 diabetes with technology that combines cellular and regenerative therapy, has signed collaborative deals with two Korean partners, a recent meeting in Seoul heard.

BioPharmaceutical Asia Pacific

Deals Shaping The Medical Industry, April 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced March 2015.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Orgenesis Inc.
  • Senior Management
  • Scott P Carmer, CEO, North America
    Neil Reithinger, CFO
    Sarah Ferber, PhD, CSO
  • Contact Info
  • Orgenesis Inc.
    Phone: (949) 574-3860
    20271 Goldenrod Ln.
    Germantown, MD 20876
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register